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Abstract
Dry eye affects 35% of population, and it is a cause of chronic pain and discomfort. The 
conventional treatment with lubricants is often not sufficient in moderate to severe cases, 
which can lead to complications such as keratopathies, corneal opacities, ocular perfora-
tions, and visual loss. Platelet-rich plasma (PRP) eyedrops have already been used in 
ocular surface diseases due to their role in epithelialization and the presence of growth 
factors and vitamins that are similar to human tears. We intend to make a literature 
review of the use of platelet-rich plasma in dry eye disease, and present the results of 
a 13 case series, of diabetic severe dry eye patients that used this alternative treatment.
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1. Introduction
In this chapter we will cover a brief literature review on the use of platelet concentrate in dry 
eye, especially in moderate and severe cases that are generally refractory to conventional treat-
ment, and we will cite some results of its use in other areas of medicine by several authors.
2. Dry eye: definition and classification
The tear has several important functions to the ocular surface, such as lubrification, transport of 
oxygen, carbon dioxide and other metabolites, immunological actions, and maintenance a stable 
corneal surface, among others. It is rich in immunoglobulins, growth factors, and vitamin A. It 
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is separated in three layers: the lipid layer, which protects the tear against evaporation and is 
secreted by Moll, Meibomian, and Zeiss glands [1]; the mucin layer produced by Manz glands, 
Henle crypts, and corneal and conjunctival cells—this one stays between the hydrophobic ocu-
lar surface and the hydrophilic tear film [2]; and the last and the most prevalent layer, the aque-
ous layer, produced by Wolfring and Krause glands [3].
The most recent definition of dry eye is that it is a multifactorial disease of the tears and 
ocular surface, which is accompanied by ocular symptoms, in which tear film instability and 
hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities 
play etiological roles [4]. The inflammation of the ocular surface can be both the cause and the 
consequence of dry eye: dysfunction of the lacrimal glands alters the tear composition, lead-
ing to hyperosmolarity that stimulates more inflammation [5], and another factor recognized 
in dry eye pathogenesis is oxidative stress [6].
There are several risk factors for dry eye, all of them are controversial. These are female sex, 
menopause therapy, omega-3 deficiency, refractive surgeries; use of some medications as antihis-
taminic drugs, antihypertensive drugs, diuretics, antidepressants, and others; hepatitis C; radia-
tion therapy; Asian race; HIV and HTLV infection; chemotherapy; isotretinoic acid use; large 
facetectomy incisions; low humidity environments; ovarian dysfunction; and sarcoidosis [7].
This disease is actually classified into two primary categories: these are tear-deficient and 
evaporative categories. The tear-deficient dry eye group generally can be due to Sjogren’s syn-
drome or non-Sjogren’s syndrome. Sjogren’s syndrome is an exocrinopathy in which lacrimal 
secretion deficiency occurs due to an autoimmune process that affects the lacrimal glands, sal-
ivary glands, and other organs of the body [8]. Non-Sjogren’s syndrome is caused by lacrimal 
diseases or lacrimal obstruction and by reflex alterations, without autoimmune factor role. 
Some causes are age-related dry eye, congenital alacrima, familial dysautonomia, sarcoidosis, 
lymphoma, AIDS (acquired immunodeficiency disease syndrome), gland denervation, lacri-
mal obstruction as in pemphigus, trigeminal injury, diabetes, neurotrophic keratopathy, use 
of contact lenses, and motor reflex block due to VII pair injury [9, 10]. The evaporative causes 
of dry eye disease are due to oil deficit, lid changes, use of contact lenses, or ocular surface 
diseases, as allergic conjunctivitis, and some of the iatrogenic dry eye that occurs after the use 
of systemic or topical medications or after surgeries or nonsurgical procedures [8, 11].
Dry eye can be also classified according to severity. One of the schemes is proposed by Delphi 
Panel [8, 12]. This classification in grades 1–4 (mild to severe) is based on the frequency or 
intensity of the dry eye symptoms and discomfort, the blurred vision and visual symptoms, 
conjunctival injection or redness, conjunctival staining, corneal staining, changes in the cor-
nea and tear as in ocular surface, alterations in the glands and lids, tear film break-up time 
(TFBUT), and Schirmer’s test values.
3. Epidemiology
Dry eye disease affects from 5 to 50% of population; this discrepancy is probably observed 
due to the absence of a consensus on the diagnosis of dry eye and the lack of standardization 
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in its classification [13]. It is more frequently in women [14], probably because of the hormone 
effects in the ocular surface and eye glands [4].
It is more common in Asia and Europe, with only one study showing the prevalence in South 
of Equator [4], and it seems to be also more frequent in older people, possibly because of the 
aging alterations in the lids, glands, ocular surface, and adnexal tissue [15].
4. Diagnosis and treatment
Diagnosis is controversial, and literature shows the lack of correlation between some objective 
tests and symptoms; this is probably due to the difficulty in understanding dry eye patho-
physiology [16].
There are some guidelines in this theme, and one of them is the American Academy of 
Ophthalmology that relates that dry eye diagnosis is obtained after a clinical approach that 
include asking the patient about exposition to dry eye risk factors and the most common 
symptoms and signs like redness, itching, photophobia, dryness, foreign body sensation, or 
pain. It is also important to ask the patient about the exposition to some kind of pollutant, if 
he is a smoker, if he has any systemic disease (like dermatological, allergic, or rheumatic dis-
eases), checking the hygiene of eyelashes and eyelids, use of medications, eyedrop use, pre-
vious ocular surgeries [17], and use of a screening questionnaire as the OSDI (Ocular Surface 
Disease Index) [18]. The clinical history is followed by a complete ophthalmological exam, 
including evaluating the eyelids, skin, nerves, visual acuity, and biomicroscopy, and some 
specific tests like tear breakup time, tear film osmolarity determination, and ocular surface 
staining with fluorescein lissamine green [4]. The assessment of the tear meniscus (less than 
0.35 mm is abnormal) can be performed, verifying if the blink rate is decreased and evaluate 
the quality of the tear (if there are mucus and debris) and corneal topography [3].
Management of dry eye disease will depend on the cause of this condition and its severity. 
There is currently no cure for dry eye, and any causal factors that are amenable to treatment 
should be treated. It includes modifications of the environment; suspension of topical or sys-
temic medications, associated with worsening when possible; artificial tear lubrification; and 
eyelid hygiene [19].
Generally, the conventional treatment is the lubricants, but it does not resolve all the cases. There 
are a wide variety of artificial tears, like 1% sodium hyaluronate, hypotonic solutions,  those that 
contains lipids or substances with bioadhesive properties and formulas that have substances that 
protects the cell’s stress; but none of them has the natural tear properties [20, 21].
Other therapies are topical cyclosporine and corticosteroids [22], but these have some disad-
vantages such as eye irritation and ocular pressure elevation and cataract, respectively [23, 24]. 
In moderate cases we can also use systemic supplements with omega-3 and linoleic acids and 
the increased consumption of water, lacrimal occlusion, and glasses use. In severe dry eye, 
in addition to all these treatments, we can take another measure like systemic cholinergic 
agonists, systemic anti-inflammatory agents, mucolytic agents, contact lenses, correction of 
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palpebral alterations, permanent lacrimal punctal occlusion, tarsorrhaphy, and, finally, the 
autologous serum tears [17].
The Ebers Papyrus 1534 BC is the first reference in the history of a blood derivative in the eye. 
In 1975, Ralph et al. used it in dry eye [25]. Fox et al. and later Tsubota related the use of autol-
ogous serum as an alternative treatment of severe dry eye cases [26, 27]. During many years 
of study, fetal bovine serum, allogenic serum, and umbilical cord serum have been used; 
however, they are heterologous, the risks of infections or allergic reactions are increased, and 
their use is not possible in any center [28]. It does not have preservative, and it is rich in vita-
mins, fibronectin, growth factors, and cytokines and has biomechanical properties similar 
to natural tear film, and they do not have preservative which is common in artificial tears 
[29]. Epidermal growth factors and vitamin A are important for proliferation, differentiation, 
and maturation of the ocular surface epithelium [30]. Fibroblast growth factor-beta is also 
involved in epithelial healing, fibronectin promotes cell migration, albumin has antiapoptopic 
activity, alpha-2-macroglobulin has anti-collagenase action, platelet-derived growth factor 
promotes hepatocytes growth factor, and substance P and insulin-like growth factor aid in 
the migration and adhesion of epithelium to the stroma [31]. The serum also maintains intra-
cellular ATP at acceptable levels and cell membrane integrity [32–35].
Some authors related the use of autologous serum drops in dry eye with some promisor 
results [35, 36].
Kojima et al. in 2005 described increased TFBUT in treated group comparing to control group 
(using artificial tears) [37]. Lee and Chen studied the use of autologous serum in 23 patients 
by 18 months and found improvements in symptoms and corneal staining pattern in approxi-
mately 75% of patients [38].
Other indications for the use of autologous serum have been the epithelial defects [39], graft-
versus-host disease [40], neurotrophic keratopathy [41], trabeculectomy ampoules [42], after 
refractive surgery [43, 44], Mooren’s ulcer [45], and other keratitis [46].
Tananuvat et al., in a randomized prospective study, found that control eyes had improve-
ment in symptoms, signs, and rose bengal staining compared with the baseline. However, some 
advantages neither Schirmer’s test results nor tear breakup time improved in treated group [34].
Urzua et al. described in a double-blind crossover clinical trial 12 severe dry eye syndrome 
patients in which autologous serum treatment showed a statistically significant higher OSDI 
decrease (50%) versus conventional treatment (22%). There were no significant changes in 
objective parameters (Oxford corneal staining and TBUT) [47]. A review to evaluate autolo-
gous serum efficacy compared to lubricants, in dry eye disease, concluded that there is a great 
heterogeneity considering the preparation and storage of the eyedrops, as well as the adequate 
use of this therapy, and that new studies that standardize these items would be necessary [19].
Another alternative, platelet-rich plasma (PRP), can be used in severe dry eye. It is prepared 
in double centrifugation of total plasma. Some of the important growth factors this hemoderi-
vate has are platelet-derived angiogenesis factor, platelet-derived epithelial growth factor, 
and platelet factor 4 [48].
The epidermal growth factor accelerates the healing process and epithelial migration in the 
cornea, besides stimulating the DNA synthesis of the epithelial cells, and is also associated 
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with the production of mucin 1 by some conjunctival cells. Transforming growth factor b1 
(TGF-b1) has an increased levels in the epithelium during corneal stromal repair processes; 
it stimulates the production of collagen, fibronectin, and proteoglycans and together with 
the platelet-derived growth factor (PDGF) has an important anti-inflammatory action [49]. 
Vitamin A is one of the major epitheliotropic factors in autologous serum; it is 100 times more 
concentrated than in natural tear and prevents squamous epithelial metaplasia [50].
Fibronectin is an important protein to corneal reepithelization, promoting healing and phago-
cytosis [51]. Annexin A5 has been investigated as an alternative to fibronectin eyedrops. It 
interacts with some integrins and stimulates the secretion of plasminogen activator-type uro-
kinase, whose expression is increased in epithelial defects. Albumin is one of the most impor-
tant proteins in the blood. It reduces the natural degradation of cytokines and growth factors 
in areas of tissue injury and shows antiapoptopic activity [39, 52, 53]. Alpha-2-macroglobulin 
neutralizes proteolytic enzymes. It is useful in ocular burns and marginal ulcers [32, 39]. 
Fibroblast growth factor-beta is a factor that promotes corneal healing, increasing cell prolif-
eration and motility [54].
The insulin-like growth factor helps epithelial cell migration [55]. Neural growth factor (NGF) 
is the most well-known neurotrophin. It restores the function of injured neurons and can be 
effective in trophic ulcers [56].
One of the PRP advantages is that it has not cytokines derived from leucocytes and monocytes, 
which are present in autologous serum and can be deleterious in patients with immune diseases 
[57]. PRP also regulates expression of several genes in the cellular differentiation improving 
biological activity of the corneal epithelial cells when compared with autologous serum [58].
The PRP protects the ocular surface from scar formation more than autologous serum, because 
of reduction of myofibroblasts. It has been observed in PRK where patients who had done this 
surgery has a decreased incidence of haze [59]. PRP causes reduction in inflammation by indi-
rect action, through the reduction of osmolarity, thus, diluting the pro-inflammatory factors 
existing in the ocular surface. This also occurs because of the presence of the growth factor-
rich plasma interleukin-1 receptor antagonist as well as the presence of metalloproteinase [60].
Platelets have a lot of important functions that are repairing tissue damage; coagulation pre-
vents blood loss, secreting proteins, cytokines, and other mediators; inducing tissue regenera-
tion by cell migration, proliferation, and angiogenesis, and preventing infections because of 
its antibiotic action. They also have an anti-inflammatory and analgesic action [61].
5. The use of PRP in medicine and odontology
Platelet-rich plasma has been used in several medical and dental areas. The platelet-rich 
plasma has approximately 1 million/ml platelets [62], and it has been used to the revitaliza-
tion of necrotic pulp teeth [63], in periodontitis [64], in revascularization of young teeth [65], 
and in other oral conditions [66].
Platelet-rich plasma has been used in orthopedic therapies like cartilage repair [67], also in 
bone regeneration, and in tendons, ligaments, and articular lesions [68].
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In dermatology, PRP has been used for wound healing of acne scars [69], vitiligo [70], venous 
ulcers [71], alopecia [72], skin rejuvenation [73], and some cases of lichen sclerosus [74].
In gynecology, there are studies where PRP had been used in cases of infertility [75], in uterine 
prolapse [76], in inducing endometrium proliferation [75], and in scars of cesarean sections [77].
It has also been used in otolaryngology [78], in urinary diseases [79], and in other medical 
specialties.
6. The use of PRP in ophthalmology
PRP has been reported in corneal ulcers [80–82], in chemical burns [83, 84], in restoration of 
lacrimal function [85], in blepharoplasties surgeries [86], in ocular surface syndrome after 
refractive surgeries [44], and in graft-versus-host disease [87].
In dry eye, there are few studies reporting the use of PRP. Alio et al., in 2007, evaluated 18 
symptomatic patients that used this treatment for 1 month and observed that symptoms 
of dry eye improved in 89% of patients, that conjunctival injection was present in 38.9% of 
patient, that 86% of the symptoms decreased, that lachrymal meniscus improved in 56% of 
the cases, and that corneal staining also decreased. In impression cytology increase in con-
junctival goblet cells was observed [88].
Ribeiro et al., had studied about diabetic dry eye patient. They evaluated 12 patients with 
grades 2–4 of severity [8, 12]; 41.67% had a reduction in Schirmer’s gradation, 58.33% had an 
increase in TFBUT (tear film breakup time), visual acuity improved in 41.66% of patients, and 
OSDI questionnaire score significantly improved in 100% of patient. The authors also found 
that before treatment, 91.67% had severe dry eye and after treatment, 50% were classified as 
normal, 25% as mild dry eye, 16.66% as moderate dry eye, and just one patient had instead a 
severe dry eye (Figures 1–5) [89].
Figure 1. Before and after treatment with PRP in patient with diabetic dry eye.
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Figure 2. Before and after treatment with PRP in patient with diabetic dry eye.
Figure 3. Before and after treatment with PRP in patient with diabetic dry eye.
Figure 4. Before and after treatment with PRP in patient with diabetic dry eye.
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Recently, in 2017, Alio reported a 368-patient prospective, interventional nonrandomized 
study, where moderate to severe dry eye was included. The results were as follows: Schirmer’s 
test value had a significant improvement, subjective symptoms had an improvement in 87.5% 
of patients, OSDI scores were statistically significant, 28.8% experienced an increase of one 
or more lines of vision, decrease in corneal fluorescein staining was observed in 76.1% of 
patients, and only one patient reported intolerance to the use of PRP due to discomfort at the 
time of instillation [90].
Another alternative that has been reported in dry eye treatment is the plasma rich in growth 
factors (PRGF). Lopez-Plandolit et al. observed that PRGF treatment was associated with 
improvement in score dry eye questionnaire values and as results from impression cytology. 
In 75% of patients, no further medication was required. But squamous metaplasia did not 
reduce significantly [49]. It is very similar to PRP; however, there are no researches in human 
use compared to all the hemoderivates in dry eye.
7. The methods of obtaining platelet-rich plasma
The two main methods of obtaining platelets are by autologous donation and by the technique 
of platelet apheresis. The advantage of the apheresis technique is that the platelet concentration 
is higher in the final concentrate and should contain at least 5.5 × 10 10 platelets, while its dis-
advantage is the cost that is extremely superior to the autologous total donation technique [48].
In the apheresis technique for platelet collection, Rezende et al. used the Haemonetics 
MCS + 9000 automatic cell separator and the 995-E apheresis-specific kit (Haemonetics Corp.). 
In that system, by means of a venipuncture, the blood of the patient himself is drained to a 
separation device. An optical refraction analyzer separates the platelet layer, and the remaining 
blood is completely returned to the patient, determining the end of a cycle. Sodium citrate can 
be used as an anticoagulant in the ratio of 1 to every 9 ml of whole blood processed. In 2 cycles, 
72 ml of platelet concentrate was collected; the hematimetric indices of the patient and also the 
platelet concentrate indices are evaluated before and after the procedure (Coulter AcT Diff) [81].
Figure 5. Before and after treatment with PRP in patient with diabetic dry eye.
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Platelet growth factors were generally obtained in a ranked room; hence, the handling of 
platelet concentrate was performed within a Category II-Type A biological safety cabinet. 
Then, 2800 microliters of 10% calcium chloride was added, and the final product was main-
tained at +37°C for approximately 30 min. Subsequently, the unit was subjected to centrifu-
gation (900G), and the supernatant serum, which contained the platelet growth factors, was 
transferred to four 50 ml falcon-type tubes (Becton-Dickinson) and maintained at −80°C 
(Revco). Research of bacteria, aerobic and anaerobic, and fungal agents was performed in a 
systematic way.
The release of serum with platelet growth factors in the study by Rezende et al. was done as 
follows: weekly, thawed Falcon tube containing approximately 10 ml of autologous serum 
with platelet growth factors that was transferred to flasks, and the patient is advised to keep 
the biological medicine at a temperature below −10°C (freezer) and to unfreeze it naturally 
immediately before each use [81].
Alio et al. used the autologous donation technique to obtain platelets, when patients were 
submitted to venipuncture and 80–100 ml of blood were collected in sterile 10 ml tubes con-
taining 1 ml of sodium citrate to avoid coagulation. These tubes were left at room temperature 
for 10 min, and only the supernatant (upper tube fraction) was collected as the final product. 
The platelet concentrate was then prepared under sterile conditions in a laminar flow room. 
Two to three milliliters of this concentrate was then placed in sterile eyedrops. The eyedrops 
were kept at −20°C, and only when the patient was going to use an eyedrop bottle, thaw it and 
then keep it at +4°C, discarding that bottle at the end of a week, when a new one is thawed. 
The patients were advised to use these eyedrops four times a day for 1 month [88].
Both methods require the patient to perform an autologous blood donation. Autologous blood 
does not transmit disease; there is no occurrence of hemolytic (alloimmunization), allergic, 
immunological (immunomodulation), or acute lung injury by transfusion and common com-
plications in heterologous donations [91].
The contraindications for autologous donations are anemia or other types of pathological 
hemodilution; conditions that lead to oxygen saturation and hemoglobin saturation (less than 
11 mg/dl); hepatopathies; nephropathies; coagulopathies; hemoglobinopathies; decompen-
sated heart diseases; and presence of infectious diseases such as Chagas, syphilis, HIV, HTLV, 
hepatitis B and C, and others transmissible by blood considered as “relative” contraindications, 
since the patient will receive the same, but there may be contamination of the health team in the 
handling of that blood. In HIV, there may be reactivation of the virus when reinfused [91, 92].
Complications of autologous donation are those inherent to a donor, such as hypotension, 
anemia, angina, and contamination of the material of the blood bags [91].
8. Conclusions
It can be concluded from these studies that the therapeutic response with PRP was actu-
ally satisfactory in severe or moderate dry eye cases which do not respond to conventional 
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therapy. However, randomized clinical trials are needed so that standardized protocols for 
the production, storage, and use of this therapy should be created. Prospective studies should 
also be conducted to evaluate these long-term outcomes.
Conflict of interest
The authors declare no conflict of interest in this subject.
Author details
Marina Viegas Moura Rezende Ribeiro1*, Eurica Adélia Nogueira Ribeiro2 and  
Luiz Feliciano Ribeiro3
*Address all correspondence to: dra.marinaribeiro@gmail.com
1 Centro Universitário Tiradentes de Alagoas, Universidade Federal de Alagoas,  
Maceió, Brazil
2 Universidade Federal de Alagoas, Maceió, Brazil
3 Instituto de Olhos de Maceió, Maceió, Brazil
References
[1] Yang H-Y et al. Lacrimal punctal occlusion for the treatment of superior limbic kerato-
conjunctivitis. American Journal of Ophthalmology. 1997;124(1):80-87
[2] Xu K-P et al. Tear function index: A new measure of dry eye. Archives of Ophthalmology. 
1995;113(1):84-88
[3] Fridman D. Associação Entre Hipoestesia Corneana, Olho Seco e Outros Fatores Em 
Portadores de Diabetes Melito Tipo 2. Tese de Mestrado—Porto Alegre: Universidade 
Federal do Rio Grande do Sul; 2004
[4] Nelson JD et al. TFOS DEWS II introduction. The Ocular Surface. 2017;15:269-275
[5] Fonseca EC, Arruda GV, Rocha EM. Olho seco: Etiopatogenia e tratamento. Arquivos 
Brasileiros de Oftalmologia. 2010;73(2):197-203
[6] Wakamatsu TH, Dogru M, Tsubota K. Tearful relations: Oxidative stress, inflammation 
and eye diseases. Arquivos Brasileiros de Oftalmologia. 2008;71(6):72-79
[7] Dry Eye Workshop. The epidemiology of dry eye disease: Report of the epidemiology 
Subcommittee of the International dry eye WorkShop. The Ocular Surface. 2007;5(2): 
93-107
Plasma Medicine - Concepts and Clinical Applications30
[8] Dry Eye Workshop. The definition and classification of dry eye disease: Report of the 
definition and classification Subcommittee of the International dry eye WorkShop. The 
Ocular Surface. 2007;5(2):75-92
[9] Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Archives 
of Ophthalmology. 2000;118(9):1264-1268
[10] Schein Oliver D et al. Dry eye and dry mouth in the elderly: A population-based assess-
ment. Archives of Internal Medicine. 1999;159(12):1359-1363
[11] Fujishima H et al. Allergic conjunctivitis and dry eye. British Journal of Ophthalmology. 
1996;80(11):994-997
[12] Behrens A et al. Dysfunctional tear syndrome: A Delphi approach to treatment recom-
mendations. Cornea. 2006;25(8):900-907
[13] Brewitt H, Sistani F. Dry eye disease: The scale of the problem. Survey of Ophthalmology. 
2001;45:S199-S202
[14] Galor A et al. Prevalence and risk factors of dry eye syndrome in a United States veterans 
affairs population. American Journal of Ophthalmology. 2011;152(3):377-384
[15] Schaumberg DA et al. Prevalence of dry eye syndrome among US women. American 
Journal of Ophthalmology. 2003;136(2):318-326
[16] Alves M et al. Comparison of diagnostic tests in distinct well-defined conditions related 
to dry eye disease. PLoS One. 2014;9(5):e97921
[17] American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern: 
Preferred Practice Pattern. Estados Unidos: AAO; 2013. Disponível em: http://www.aao.
org/preferred-practice-pattern/dry-eye-syndrome-ppp-201
[18] Schiffman RM et al. Reliability and validity of the ocular surface disease index. Archives 
of Ophthalmology. 2000;118(5):615-621
[19] Pan Q et al. Autologous serum eye drops for dry eye. Cochrane Database of Systematic 
Reviews. 2013;8
[20] Aragona P et al. Effects of amino acids enriched tears substitutes on the cornea of patients 
with dysfunctional tear syndrome. Acta Ophthalmologica. 2013;91(6)
[21] Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: Role in tissue main-
tenance, wound healing, and ocular pathology. The Ocular Surface. 2007;5(3):228-239
[22] Pflugfelder SC. Antiinflammatory therapy for dry eye. American Journal of Ophthal-
mology. 2004;137(2):337-342
[23] Blomquist PH, Palmer BF. Ocular complications of systemic medications. The American 
Journal of the Medical Sciences. 2011;342(1):62-69
[24] Wang Y et al. Ocular surface and tear functions after topical cyclosporine treatment in 
dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplantation. 
2008;41(3):293
The Use of Platelet-Rich Plasma in Dry Eye Disease
http://dx.doi.org/10.5772/intechopen.76090
31
[25] Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion 
pump. Archives of Ophthalmology. 1975;93(10):1039-1043
[26] Tsubota K et al. Surgical reconstruction of the ocular surface in advanced ocular cicatri-
cial pemphigoid and Stevens-Johnson syndrome. American Journal of Ophthalmology. 
1996;122(1):38-52
[27] Fox RI et al. Beneficial effect of artificial tears made with autologous serum in patients 
with keratoconjunctivitis sicca. Arthritis & Rheumatology. 1984;27(4):459-461
[28] Yoon K-C et al. Comparison of autologous serum and umbilical cord serum eye drops 
for dry eye syndrome. American Journal of Ophthalmology. 2007;144(1):86-92
[29] Liu L et al. An optimised protocol for the production of autologous serum eyedrops. 
Graefe's Archive for Clinical and Experimental Ophthalmology. 2005;243(7):706-714
[30] Woost PG et al. Growth factors and corneal endothelial cells: I. Stimulation of bovine cor-
neal endothelial cell DNA synthesis by defined growth factors. Cornea. 1992;11(1):1-10
[31] Oftalmología, Aplicaciones Del Suero Autólogo En. Use of autologous serum in ophthal-
mic practice. Archivos de la Sociedad Española de Oftalmología. 2007;82:9-20
[32] Poon AC et al. Autologous serum eyedrops for dry eyes and epithelial defects: Clinical 
and in vitro toxicity studies. British Journal of Ophthalmology. 2001;85(10):1188-1197
[33] Koffler BH. Autologous serum therapy of the ocular surface with novel delivery by 
platelet concentrate gel. The Ocular Surface. 2006;4(4):188-195
[34] Tananuvat N et al. Controlled study of the use of autologous serum in dry eye patients. 
Cornea. 2001;20(8):802-806
[35] Young HJ, Lee YJ, Yun P-Y. Management of ocular surface inflammation in Sjögren syn-
drome. Cornea. 2007;26:S13-S15
[36] Noble BA et al. Comparison of autologous serum eye drops with conventional therapy 
in a randomised controlled crossover trial for ocular surface disease. The British Journal 
of Ophthalmology. 2004;88(5):647-652
[37] Kojima T et al. The effect of autologous serum eyedrops in the treatment of severe 
dry eye disease: A prospective randomized case-control study. American Journal of 
Ophthalmology. 2005;139(2):242-246
[38] Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syn-
drome. Clinical & Experimental Ophthalmology. 2008;36(2):119-122
[39] Tsubota K et al. Treatment of persistent corneal epithelial defect by autologous serum 
application. Ophthalmology. 1999;106(10):1984-1989
[40] Mixon B et al. Autologous serum eye drops for severe dry eye syndrome in a patient with 
chronic graft-versus-host disease: A case report. International Journal of Pharmaceutical 
Compounding. 2013;18(5):370-377
Plasma Medicine - Concepts and Clinical Applications32
[41] Matsumoto Y et al. Autologous serum application in the treatment of neurotrophic kera-
topathy. Ophthalmology. 2004;111(6):1115-1120
[42] Matsuo H et al. Topical application of autologous serum for the treatment of late-onset 
aqueous oozing or point-leak through filtering bleb. Eye. 2005;19(1):23
[43] Noda-Tsuruya T et al. Autologous serum eye drops for dry eye after LASIK. Journal of 
Refractive Surgery. 2006;22(1):61-66
[44] Javaloy J et al. Effect of platelet-rich plasma in nerve regeneration after LASIK. Journal 
of Refractive Surgery. 2013;29(3):213-219
[45] Mavrakanas A, Kiel R, Dosso AA. Autologous serum application in the treatment of 
Mooren’s ulcer. Klinische Monatsblätter für Augenheilkunde. 2007;224(4):300-302
[46] López-García JS et al. Autologous serum eyedrops in the treatment of aniridic keratopa-
thy. Ophthalmology. 2008;115(2):262-267
[47] Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind 
clinical trial of autologous serum versus artificial tears in dry eye syndrome. Current Eye 
Research. 2012;37(8):684-688
[48] Razouk FH, Edna R. Characterization, production and indication of the principal blood 
components. Revista Brasileira de Hematologia e Hemoterapia. 2004;26(2):126-134
[49] López-Plandolit S et al. Efficacy of plasma rich in growth factors for the treatment of dry 
eye. Cornea. 2011;30(12):1312-1317
[50] Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface 
disorders. British Journal of Ophthalmology. 2004;88(11):1467-1474
[51] Mai PT et al. Topical fibronectin in an alkali burn model of corneal ulceration in rabbits. 
Archives of Ophthalmology. 1991;109(3):414-419
[52] Unterlauft JD et al. Albumin eye drops for treatment of ocular surface diseases. Der 
Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2009;106(10): 
932-937
[53] Shimmura S et al. Albumin as a tear supplement in the treatment of severe dry eye. 
British Journal of Ophthalmology. 2003;87(10):1279-1283
[54] Jens LA, Ehlers N. Chemotaxis of human keratocytes is increased by platelet-derived 
growth factor-BB, epidermal growth factor, transforming growth factor-alpha, acidic 
fibroblast growth factor, insulin-like growth factor-I, and transforming growth factor-
beta. Current Eye Research. 1998;17(1):79-87
[55] Yamada N et al. Role of the c domain of IGFs in synergistic promotion, with a sub-
stance P–derived peptide, of rabbit corneal epithelial wound healing. Investigative 
Ophthalmology & Visual Science. 2004;45(4):1125-1131
The Use of Platelet-Rich Plasma in Dry Eye Disease
http://dx.doi.org/10.5772/intechopen.76090
33
[56] Matsuura N et al. Predominance of infiltrating IL-4-producing T cells in conjunctiva of 
patients with allergic conjunctival disease. Current Eye Research. 2004;29(4-5):235-243
[57] Gomes B et al. Signs and symptoms of ocular surface disease in patients on topical 
intraocular pressure-lowering therapy. Arquivos Brasileiros de Oftalmologia. 2013;76 
(5):282-287
[58] Freire V et al. In vitro effects of three blood derivatives on human corneal epithelial 
cells blood derivatives in human corneal epithelial cells. Investigative Ophthalmology & 
Visual Science. 2012;53(9):5571-5578
[59] Eduardo A et al. Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound 
healing and reduces haze formation after PRK surgery. Experimental Eye Research. 
2013;115:153-161
[60] Alio JL et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal 
ulcers. Ophthalmology. 2007;114(7):1286-1293
[61] Amable PR, Carias RBV, Teixeira MVT, da Cruz Pacheco Í, Corrêa do Amaral RJF, 
Granjeiro JM, Borojevic R. Platelet-rich plasma preparation for regenerative medicine: 
Optimization and quantification of cytokines and growth factors. Stem Cell Research & 
Therapy. 2013;4(3):67
[62] Brass L. Understanding and evaluating platelet function. Hematology/the Education 
Program of the American Society of Hematology American Society of Hematology 
Education Program. 2010;2010:387-396
[63] Torabinejad M, Turman M. Revitalization of tooth with necrotic pulp and open apex 
by using platelet-rich plasma: A case report. Journal of Endodontia. 2011;37(2):265-268
[64] Banchs F, Trope M. Revascularization of immature permanent teeth with apical peri-
odontitis: New treatment protocol? Journal of Endodontics. 2004;30(4):196-200
[65] Jadhav G, Shah N, Logani A. Revascularization with and without platelet-rich plasma 
in nonvital, immature, anterior teeth: A pilot clinical study. Journal of Endodontics. 
2012;38(12):1581-1587
[66] Shah N, Logani A, Bhaskar U, Aggarwal V. Efficacy of revascularization to induce apexi-
fication/apexogensis in infected, nonvital, immature teeth: A pilot clinical study. Journal 
of Endodontia. 2008;34(8):919-925
[67] Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in 
cartilage repair. Arthritis Research & Therapy. 2014;16(1):204
[68] Brossi PM et al. Platelet-rich plasma in Orthopedic therapy: A comparative systematic 
review of clinical and experimental data in equine and human musculoskeletal lesions. 
BMC Veterinary Research. 2015;11:98
[69] Gawdat HI, Hegazy RA, Fawzy MM, Fathy M. Autologous platelet rich plasma: Topical 
versus intradermal after fractional ablative carbon dioxide laser treatment of atrophic 
acne scars. Dermatologic Surgery. 2014;40(2):152-161
Plasma Medicine - Concepts and Clinical Applications34
[70] Abdelghani R, Ahmed NA, Darwish HM. Combined treatment with fractional carbon 
dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vit-
iligo in different body sites: A prospective, randomized comparative trial. Journal of 
Cosmetic Dermatology; 2017
[71] Cervelli V, Gentile P, Grimaldi M. Regenerative surgery: Use of fat grafting combined 
with platelet-rich plasma for chronic lower-extremity ulcers. Aesthetic Plastic Surgery. 
2009;33(3):340
[72] Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. A random-
ized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects 
of platelet-rich plasma on alopecia areata. British Journal of Dermatology. 2013;169(3): 
690-694
[73] Kim DH, Je YJ, Kim CD, Lee YH, Seo YJ, Lee JH, Lee Y. Can platelet-rich plasma be used 
for skin rejuvenation? Evaluation of effects of platelet-rich plasma on human dermal 
fibroblast. Annals of Dermatology. 2011;23(4):424-431
[74] Casabona F, Priano V, Vallerino V, Cogliandro A, Lavagnino G. New surgical approach 
to lichen sclerosus of the vulva: The role of adipose-derived mesenchymal cells 
and platelet-rich plasma in tissue regeneration. Plastic and Reconstructive Surgery. 
2010;126(4):210e-211e
[75] Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Autologous platelet-rich plasma 
promotes endometrial growth and improves pregnancy outcome during in vitro fertil-
ization. International Journal of Clinical and Experimental Medicine. 2015;8(1):1286
[76] Chrysanthopoulou EL, Pergialiotis V, Perrea D, Κourkoulis S, Verikokos C, Doumouchtsis 
SK. Platelet rich plasma as a minimally invasive approach to uterine prolapse. Medical 
Hypotheses; 2017
[77] Tehranian A, Esfehani-Mehr B, Pirjani R, Rezaei N, Heidary SS, Sepidarkish M. Application 
of autologous platelet-rich plasma (PRP) on wound healing after caesarean section in 
high-risk patients. Iranian Red Crescent Medical Journal. 2016;18(7):e34449
[78] Stavrakas M, Karkos PD, Markou K, Grigoriadis N. Platelet-rich plasma in otolaryngol-
ogy. The Journal of Laryngology and Otology. 2016;130(12):1098-1102
[79] Nikolopoulos KI, Pergialiotis V, Perrea D, Doumouchtsis SK. Restoration of the pubo-
urethral ligament with platelet rich plasma for the treatment of stress urinary inconti-
nence. Medical Hypotheses. 2016;90:29-31
[80] Kim KM, Shin Y-T, Kim HK. Effect of autologous platelet-rich plasma on persistent 
corneal epithelial defect after infectious keratitis. Japanese Journal of Ophthalmology. 
2012;56(6):544-550
[81] Rezende MSVM et al. Uso do concentrado de plaquetas em doença da superfície ocular. 
Revista Brasileira de Oftalmologia. 2007;66(4):257-261
The Use of Platelet-Rich Plasma in Dry Eye Disease
http://dx.doi.org/10.5772/intechopen.76090
35
[82] Alio JL, Rodriguez AE, Wróbel Dudzinska D. Eye platelet-rich plasma in the treatment 
of ocular surface disorders. Current Opinion in Ophthalmology. 2015;26(4):325-332
[83] Marquez DADCR, De EEIM. Subconjunctival application of regenerative factor-rich 
plasma for the treatment of ocular alkali burns. European Journal of Ophthalmology. 
2009;19(6):909-915
[84] Panda A et al. Topical autologous platelet-rich plasma eyedrops for acute corneal chemi-
cal injury. Cornea. 2012;31(9):989-993
[85] Avila MY. Restoration of human lacrimal function following platelet-rich plasma injec-
tion. Cornea. 2014;33(1):18-21
[86] Vick VL et al. Use of autologous platelet concentrate in blepharoplasty surgery. 
Ophthalmic Plastic & Reconstructive Surgery. 2006;22(2):102-104
[87] Pezzotta S et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone 
Marrow Transplantation. 2012;47(12):1558
[88] Alio JL et al. Symptomatic dry eye treatment with autologous platelet-rich plasma. 
Ophthalmic Research. 2007;39(3):124-129
[89] Ribeiro MVMR et al. Platelet-rich plasma in diabetic dry eye disease. Revista Brasileira 
de Oftalmologia. 2016;75(4):308-313
[90] Alio JL et al. Treatment of dry eye disease with autologous platelet-rich plasma: A pro-
spective, interventional, non-randomized study. Ophthalmology and therapy. 2017:1-9
[91] Vane LA, Ganem EM. Doação homóloga versus autóloga e substitutos da hemoglobina. 
Medicina Perioperatória. 2006:292-306
[92] Hospital Sírio Libanês. Guia de Condutas Hemoterápicas. São Paulo: Hospital Sírio 
Libanês; 2010
Plasma Medicine - Concepts and Clinical Applications36
